Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Simulations Plus ( (SLP) ) has issued an update.
On July 14, 2025, Simulations Plus reported its third quarter fiscal 2025 financial results, showing a 10% increase in total revenue to $20.4 million compared to the previous year. Despite a net loss of $67.3 million due to a non-cash impairment charge, the company saw growth in both software and services revenue. The company also implemented a strategic reorganization to streamline operations and focus on AI-driven initiatives to maintain its competitive edge in the biosimulation market.
The most recent analyst rating on (SLP) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Simulations Plus stock, see the SLP Stock Forecast page.
Spark’s Take on SLP Stock
According to Spark, TipRanks’ AI Analyst, SLP is a Neutral.
Simulations Plus demonstrates solid financial health and promising revenue growth, particularly in the software segment. However, technical analysis reveals bearish momentum, and the stock appears overvalued with a high P/E ratio. Positive earnings call and corporate events suggest potential for future growth, though challenges with project initiation and margins remain concerns.
To see Spark’s full report on SLP stock, click here.
More about Simulations Plus
Simulations Plus, Inc. is a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry.
Average Trading Volume: 415,912
Technical Sentiment Signal: Sell
Current Market Cap: $341.1M
For detailed information about SLP stock, go to TipRanks’ Stock Analysis page.